Post-Transplant Liver Assessment: Liver Transplantation | April 2026

Introduction

Liver transplantation has dramatically improved survival in patients with end-stage liver disease and hepatocellular carcinoma. However, long-term outcomes are often compromised by complications such as graft rejection, recurrent disease, or de novo liver pathology leading to fibrosis and cirrhosis. Traditionally, monitoring relies on invasive methods like liver biopsy, but increasing attention is being given to Non-invasive tests as safer alternatives.

Problem Statement

The role and optimal application of non-invasive tests in post-transplant liver assessment remain unclear and are not yet standardized in routine clinical practice.

Summary

This review emphasizes the emerging role of non-invasive tests in monitoring liver graft health after transplantation. NITs—including tools for assessing fibrosis, steatosis, and portal hypertension—have already transformed management in native liver disease, but their translation into the post-transplant setting is still evolving.

The authors highlight that NITs can potentially detect early graft dysfunction, reducing the need for repeated biopsies and enabling closer, safer monitoring. However, interpretation in the transplant setting is more complex due to factors such as immunosuppression, vascular changes, and mixed etiologies of graft injury.

A key takeaway is the need for contextual interpretation—NIT results should not be used in isolation but integrated with clinical, biochemical, and imaging data. Despite current limitations, NITs offer a promising pathway toward personalized, longitudinal graft surveillance, allowing earlier intervention and improved long-term outcomes.

Overall, this review supports a gradual shift from invasive to non-invasive monitoring strategies in post-transplant care, while emphasizing the need for further validation and standardized protocols.